Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

British Journal of Cancer

Volumn 106, Issue 4, 2012, Pages 646-650

  Cella, D ^a   Bushmakin, A G ^b   Cappelleri, J C ^b   Charbonneau, C ^b   Michaelson, M D ^c   Motzer, R J ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

metastatic renal cell carcinoma; prognostic tool; quality of life; sunitinib; survival; Weibull model

Indexed keywords

ALPHA INTERFERON; SUNITINIB;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PYRROLES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84856909356     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.589     Document Type: Article

References (24)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control 19: 716-723
2. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F, Patard JJ (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175: 859-863 (Pubitemid 43199997)
3. Bukowski R, Cella D, Gondek K, Escudier B, Sorafenib TARGETs Clinical Trial Group (2007) Effects of sorafenib on symptoms and quality of life: Results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30: 220-227 (Pubitemid 46884139)
4. Cella D, Cappelleri JC, Bushmakin A, Charbonneau C, Li JZ, Kim ST, Chen I, Michaelson MD, Motzer RJ (2009) Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon alfa. J Oncol Pract 5: 66-70
5. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon-alfa: Results from a phase III randomized trial. J Clin Oncol 26: 3763-3769
6. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, Li JZ, Motzer RJ (2010) Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferonalpha in a phase III trial: Final results and geographic analysis. Br J Cancer 102: 658-664
7. Cella D, Yount S, Brucker PS, Du H, Bukowski R, Vogelzang N, Bro WP (2007) Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10: 285-293 (Pubitemid 47077253)
8. Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, George J, Bro WP, Kelly C, Bukowski R (2006) Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4: 191-199 (Pubitemid 43890980)
9. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11: 570-579 (Pubitemid 23071057)
10. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543-550 (Pubitemid 47106142)
11. Chow LQ, Eckhardt SG (2007) Sunitinib: From rational design to clinical efficacy. J Clin Oncol 25: 884-896 (Pubitemid 350002890)
12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
13. Kleinbaum DG, Klein M (2005) Survival Analysis: A Self-Learning Text, 2nd edn. Springer Science + Business Media, Inc.: New York, NY
14. Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH (2007) Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Tumori 93: 68-74 (Pubitemid 46506531)
15. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296 (Pubitemid 34032623)
16. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463 (Pubitemid 41079774)
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124 (Pubitemid 46089672)
19. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib-targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22: 295-300
20. SAS Institute Inc. (2008). SAS/STATs 9.2 User's Guide. SAS Institute Inc.: Cary, NC
21. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI (2010) Treatment of metastatic renal cell carcinoma. Nat Rev Urol 7: 327-338
22. Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, Negrier S, Andresen SW, Bukowski RM (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107: 1793-1800 (Pubitemid 44582948)
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
24. Trask PC, Bushmakin AG, Cappelleri JC, Tarazi J, Rosbrook B, Bycott P, Kim S, StadlerWM, Rini B (2011) Baseline patient-reported kidney cancerspecific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Survivorship 5: 255-262